|Bid||1.3400 x 43500|
|Ask||1.3500 x 39400|
|Day's Range||1.2800 - 1.3700|
|52 Week Range||1.1200 - 2.5450|
|Beta (5Y Monthly)||1.19|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Agrivalle, a leading Brazilian agricultural biologicals company, today announced a new partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. Together, the companies will collaborate on building cutting edge technologies to advance Agrivalle's biological products, including next-gen fertilizers and biocontrol agents.
Synplogen Co., a synthetic biology startup spun out of Kobe University's Graduate School of Science, Technology and Innovation that provides custom DNA synthesis and Gene Therapy Biofoundry services, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a non-binding Memorandum of Understanding ("MOU"). Together, Synplogen and Ginkgo intend to accelerate the global development of DNA manufacturing
Vivici BV, an innovative B2B ingredients startup company using precision fermentation to make animal-free dairy proteins, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Through this collaboration, Vivici will leverage Ginkgo's extensive capabilities in strain engineering, optimization and performance, to develop and commercialize a next generation of functional alternative protein.